Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-7451. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 20/20 | 0.76 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | FGR | P09769 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | SIK1 | P57059 | 1/20 | 0.58 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.58 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-7451 SCHEMBL29690227 | 1.00 | NTRK1 (0.76) | NTRK1JAK2ALKABL1FGR | |
| Azd-7451 SCHEMBL18797141 | 1.00 | NTRK1 (0.76) | NTRK1JAK2ALKABL1FGR | |
| Azd-7451 SCHEMBL29690374 | 0.95 | NTRK1 (0.72) | NTRK1JAK2ALKABL1FGR | |
| Azd-7451 SCHEMBL29073122 | 0.95 | NTRK1 (0.72) | NTRK1JAK2ALKABL1FGR | |
| Azd-7451 SCHEMBL29073123 | 0.95 | NTRK1 (0.72) | NTRK1JAK2ALKABL1FGR | |
| SCHEMBL3773386 | 0.90 | NTRK1 (0.75) | NTRK1JAK2ALKABL1FGR | |
| SCHEMBL3775459 | 0.90 | NTRK1 (0.60) | NTRK1JAK2ALKABL1FGR | |
| SCHEMBL3777718 | 0.89 | NTRK1 (0.77) | NTRK1JAK2ALKABL1FGR | |
| SCHEMBL3705688 | 0.88 | NTRK1 (0.59) | NTRK1JAK2ALKABL1FGR | |
| SCHEMBL3773405 | 0.87 | NTRK1 (1.00) | NTRK1JAK2ALKABL1FGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | claimed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | claimed |
| EP-3368039-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | The Regents of The University of Colorado, A Body Corporate (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2017075107-A9 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-08-02 | — | — | WO | claimed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | claimed |
| WO-2017075107-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NANDA NISHA (US) | 2017-05-04 | — | — | WO | claimed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2023248151-A1 | METHOD OF TREATING SKIN FIELD CANCERIZATION WITH ACTINIC KERATOSES | PYRAMID BIOSCIENCES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-116782883-A | Topical pharmaceutical compositions and methods | 金字塔生物科技公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116782883-A | Topical pharmaceutical compositions and methods | 金字塔生物科技公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2022144758-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| WO-2008135785-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | NTRK1 3/4885JAK2 2121/4885ALK 140/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885ALK 89/4885 |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | TP53, NCOA3, NCOA1 | NTRK1 21/4885JAK2 1391/4885ALK 369/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1312/4885ALK 96/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885JAK2 1349/4885ALK 89/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | NTRK1 4038/4885JAK2 81/4885ALK 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.